Oruka Therapeutics (NASDAQ:ORKA) Earns “Buy” Rating from HC Wainwright

Oruka Therapeutics (NASDAQ:ORKA)‘s stock had its “buy” rating restated by investment analysts at HC Wainwright in a note issued to investors on Thursday, Benzinga reports. They presently have a $120.00 target price on the stock. HC Wainwright’s price target points to a potential upside of 33.44% from the company’s current price.

Other analysts have also issued research reports about the company. Guggenheim reissued a “buy” rating and set a $200.00 price target on shares of Oruka Therapeutics in a report on Tuesday, August 11th. BTIG Research reaffirmed a “buy” rating and set a $151.00 price target on shares of Oruka Therapeutics in a report on Tuesday, August 11th. UBS Group increased their price objective on shares of Oruka Therapeutics from $100.00 to $130.00 and gave the stock a “buy” rating in a research note on Wednesday, July 1st. Weiss Ratings upgraded Oruka Therapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Wednesday, July 15th. Finally, Wall Street Zen downgraded Oruka Therapeutics from a “hold” rating to a “sell” rating in a research note on Sunday, August 16th. Ten equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $133.00.

Oruka Therapeutics Stock Down 4.9%

Shares of ORKA stock opened at $89.93 on Thursday. The firm has a market capitalization of $5.95 billion, a price-to-earnings ratio of -44.30 and a beta of -0.34. The stock has a fifty day moving average of $96.79 and a 200 day moving average of $75.32. Oruka Therapeutics has a 52 week low of $14.89 and a 52 week high of $115.51.

Oruka Therapeutics (NASDAQ:ORKA) last issued its quarterly earnings results on Monday, August 10th. The company reported ($0.55) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.51) by ($0.04). Equities research analysts anticipate that Oruka Therapeutics will post -2.42 earnings per share for the current year.

Insider Buying and Selling at Oruka Therapeutics

In other news, CEO Lawrence Klein sold 75,000 shares of the company’s stock in a transaction that occurred on Tuesday, September 1st. The stock was sold at an average price of $91.83, for a total transaction of $6,887,250.00. Following the transaction, the chief executive officer owned 925,580 shares of the company’s stock, valued at approximately $84,996,011.40. This represents a 7.50% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Joana Goncalves sold 7,947 shares of the business’s stock in a transaction on Tuesday, September 15th. The shares were sold at an average price of $92.38, for a total value of $734,143.86. Following the transaction, the insider owned 31,771 shares of the company’s stock, valued at approximately $2,935,004.98. The trade was a 20.01% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders sold 122,950 shares of company stock worth $11,528,806 over the last 90 days. Company insiders own 23.49% of the company’s stock.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently added to or reduced their stakes in ORKA. Nykredit A S bought a new stake in shares of Oruka Therapeutics in the 2nd quarter valued at about $29,000. Orion Capital Management LLC purchased a new stake in Oruka Therapeutics during the second quarter worth $91,000. Natural Investments LLC bought a new stake in Oruka Therapeutics during the 2nd quarter valued at $202,000. Caitong International Asset Management Co. Ltd purchased a new position in shares of Oruka Therapeutics in the 4th quarter valued at $67,000. Finally, Connor Clark & Lunn Investment Management Ltd. purchased a new stake in shares of Oruka Therapeutics during the 2nd quarter worth $211,000. 56.44% of the stock is currently owned by institutional investors.

Oruka Therapeutics News Summary

Here are the key news stories impacting Oruka Therapeutics this week:

• Positive Sentiment: ORKA-001 produced deepening psoriasis responses without additional dosing after Week 4. By Week 28, the PASI 100 response rate reached 71.4% and the PASI 90 rate reached 87.3%, supporting the potential for durable disease control from the half-life-extended IL-23p19 antibody. Oruka Therapeutics Week 28 Data Announcement
• Positive Sentiment: Patients who crossed over from placebo also achieved PASI 90 and PASI 100 response rates comparable to those initially treated with ORKA-001, while the therapy maintained a favorable safety and tolerability profile through Week 28. EVERLAST-A Week 28 Results
• Neutral Sentiment: The results remain from a mid-stage Phase 2a study, so investors still need larger and later-stage data to assess efficacy, durability, safety, and the drug’s competitiveness against established psoriasis treatments. The company expects full 52-week EVERLAST-A data in December 2026 and EVERLAST-B Week 16 data in the fourth quarter of 2026. What the Phase 2a Data Means for Shareholders
• Negative Sentiment: Despite the improving response rates, ORKA shares fell as investors appeared to treat the update as insufficient for further upside, potentially reflecting profit-taking and high expectations already embedded in the stock. Reports specifically highlighted that the shares declined despite the deepening responses. Oruka Shares Fall Despite Deepening Week 28 Responses

About Oruka Therapeutics

Oruka Therapeutics, Inc (NASDAQ:ORKA) is a clinical-stage biotechnology company developing long-acting monoclonal antibody therapies for immune-mediated diseases. The company’s research is focused on creating medicines that may allow less frequent dosing than existing biologic treatments.

Oruka’s initial development programs are aimed at inflammatory conditions, including psoriasis. Its pipeline includes engineered antibody candidates designed to target important immune pathways, including interleukin-23 and interleukin-17.